Hot Features
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. ... 20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0499 | 8.90912337083 | 0.5601 | 0.7 | 0.5111 | 556891 | 0.5985446 | CS |
| 4 | -0.25 | -29.0697674419 | 0.86 | 0.989 | 0.5111 | 1832640 | 0.86101653 | CS |
| 12 | -1.26 | -67.3796791444 | 1.87 | 1.99 | 0.5111 | 826634 | 0.91859554 | CS |
| 26 | -18.79 | -96.8556701031 | 19.4 | 19.4 | 0.5111 | 659012 | 1.46089337 | CS |
| 52 | -18.79 | -96.8556701031 | 19.4 | 19.4 | 0.5111 | 659012 | 1.46089337 | CS |
| 156 | -18.79 | -96.8556701031 | 19.4 | 19.4 | 0.5111 | 659012 | 1.46089337 | CS |
| 260 | -18.79 | -96.8556701031 | 19.4 | 19.4 | 0.5111 | 659012 | 1.46089337 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.